Prediction model for respiratory-related mortality in microscopic polyangiitis with interstitial lung disease: multicenter REVEAL cohort study.

Microscopic polyangiitis high-resolution computed tomography scoring interstitial lung disease pulmonary function tests

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
26 Aug 2023
Historique:
received: 27 01 2023
revised: 11 06 2023
accepted: 28 07 2023
medline: 27 8 2023
pubmed: 27 8 2023
entrez: 26 8 2023
Statut: aheadofprint

Résumé

This study aimed to establish prediction models for respiratory-related mortality in microscopic polyangiitis (MPA) complicated by interstitial lung disease (ILD) using clinical characteristics. We enrolled patients with MPA with ILD between May 2005 and June 2021 in a multicentre cohort of Japanese patients with MPA (REVEAL cohort). We evaluated the demographic, clinical, laboratory, radiological findings, treatments, and the presence of honeycombing 1 cm above the diaphragm using chest high-resolution computed tomography (HRCT) on admission. We explored the risk factors predictive of respiratory-related mortality. Of 115 patients, 26 cases died of respiratory-related diseases during a median follow-up of 3.8 years. Eighteen patients (69%) died due to respiratory infection, three (12%) had diffuse alveolar hemorrhage (DAH), and five (19%) had exacerbation of ILD. In univariate analysis, older age, lower percent forced vital capacity (%FVC), lower percent diffusing capacity of carbon monoxide (%DLco), and the presence of honeycombing in the right lower lobe were identified as risk factors. Additionally, in multivariate analysis adjusted for age and treatment, %FVC, %DLco, and the presence of honeycombing in the right lower lobe were independently associated with respiratory-related mortality. We created prediction models based on the values of %FVC, %DLco, and presence of honeycombing on chest HRCT (MPF model). The 5-year respiratory-related death-free rate was significantly different between patients with MPA with ILD stratified by the number of risk factors based on the MPF model. Our study indicates that the MPF model may help predict respiratory-related death in patients with MPA with ILD.

Identifiants

pubmed: 37632776
pii: 7252229
doi: 10.1093/rheumatology/kead444
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Shogo Matsuda (S)

Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Takuya Kotani (T)

Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Ayana Okazaki (A)

Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Daisuke Nishioka (D)

Department of Medical Statistics, Research & Development Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Ryu Watanabe (R)

Department of Clinical Immunology, Osaka Metropolitan University, Osaka, Japan.

Takaho Gon (T)

Department of Clinical Immunology, Osaka Metropolitan University, Osaka, Japan.

Atsushi Manabe (A)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Mikihito Shoji (M)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Keiichiro Kadoba (K)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Ryosuke Hiwa (R)

Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Wataru Yamamoto (W)

Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.

Motomu Hashimoto (M)

Department of Clinical Immunology, Osaka Metropolitan University, Osaka, Japan.

Tohru Takeuchi (T)

Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Classifications MeSH